Bullous Pemphigoid: Physiopathology, Clinical Features and Management

Advances in Dermatology

Volumn 23, Issue , 2007, Pages 257-288

  Di Zenzo, Giovanni ^a   Marazza, Gionata ^b   Borradori, Luca ^b  

^a LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; CARRIER PROTEIN; COLLAGEN TYPE 17; CYTOSKELETON PROTEIN; DST PROTEIN, HUMAN; IMMUNOSUPPRESSIVE AGENT; NERVE PROTEIN; NONFIBRILLAR COLLAGEN; UNCLASSIFIED DRUG;

BULLOUS PEMPHIGOID; HEMIDESMOSOME; HUMAN; IMMUNOLOGICAL PROCEDURES; IMMUNOLOGY; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; REVIEW;

AUTOANTIBODIES; AUTOANTIGENS; CARRIER PROTEINS; CYTOSKELETAL PROTEINS; HEMIDESMOSOMES; HUMANS; IMMUNOLOGIC TESTS; IMMUNOSUPPRESSIVE AGENTS; NERVE TISSUE PROTEINS; NON-FIBRILLAR COLLAGENS; PEMPHIGOID, BULLOUS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 36049048308     PISSN: 08820880     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.yadr.2007.07.013     Document Type: Review

References (164)

1. Zillikens D., Wever S., Roth A., et al. Incidence of autoimmune subepidermal blistering dermatoses in a region of central Germany. Arch Dermatol 131 (1995) 957-958
2. Bernard P., Vaillant L., Labeille B., et al. Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Bullous Diseases French Study Group. Arch Dermatol 131 (1995) 48-52
3. Jung M., Kippes W., Messer G., et al. Increased risk of bullous pemphigoid in male and very old patients: a population-based study on incidence. J Am Acad Dermatol 41 (1999) 266-268
4. Rzany B., and Weller N. Epidemiology of autoimmune skin disorders. In: Hertl M. (Ed). Autoimmune diseases of the skin (2005), Springer Verlag, Wien-New York 21-38
5. Baricault S., Sparsa A., Courville P., et al. Incidence de la pemphigoïde bulleuse. Ann Dermatol Venereol 133 (2006) 4S1-4S2 - C2
6. *0301 is present in clinical variants of pemphigoid. Proc Natl Acad Sci USA 93 (1996) 8569-8571
7. Lever W.F. Pemphigus. Medicine (Baltimore) 32 (1953) 1-123
8. Liu H.N., Su W.P., and Rogers III R.S. Clinical variants of pemphigoid. Int J Dermatol 25 (1986) 17-27
9. Korman N. Bullous pemphigoid. J Am Acad Dermatol 16 (1987) 907-924
10. Laffitte E., and Borradori L. Bullous pemphigoid and related disorders. In: Hertl M. (Ed). Autoimmune diseases of the skin (2005), Springer Verlag, Wien-New York 63-83
11. Castanet J., Lacour J.P., and Ortonne J.P. Atypical clinical forms of bullous pemphigoid. Ann Dermatol Venereol 117 (1990) 73-82
12. Salomon R.J., Briggaman R.A., Wernikoff S.Y., et al. Localized bullous pemphigoid. A mimic of acute contact dermatitis. Arch Dermatol 123 (1987) 389-392
13. Callens A., Vaillant L., Machet M.C., et al. Localized atypical pemphigoid on lymphedema following radiotherapy. Acta Derm Venereol 73 (1993) 461-464
14. Ernst T.M., and Marsch W.C. Develop of localized pemphigoid following radiation treatment. Dermatologica 164 (1982) 73-81
15. Borradori L., Prost C., Wolkenstein P., et al. Localized pretibial pemphigoid and pemphigoid nodularis. J Am Acad Dermatol 27 (1992) 863-867
16. Person J.R. Hydrostatic bullae and pretibial pemphigoid. Int J Dermatol 22 (1983) 237-238
17. Nunzi E., Rongioletti F., Parodi A., et al. Dyshidrosiform pemphigoid. J Am Acad Dermatol 19 (1988) 568-569
18. Descamps V., Flageul B., Vignon-Pennamen D., et al. Dyshidrosiform pemphigoid: report of three cases. J Am Acad Dermatol 26 (1992) 651-652
19. Farrell A.M., Kirtschig G., Dalziel K.L., et al. Childhood vulval pemphigoid: a clinical and immunopathological study of five patients. Br J Dermatol 140 (1999) 308-312
20. Bean S.F., Michel B., Furey N., et al. Vesicular pemphigoid. Arch Dermatol 112 (1976) 1402-1404
21. Ohnishi Y., Tajima S., Ishibashi A., et al. A vesicular bullous pemphigoid with an autoantibody against plectin. Br J Dermatol 142 (2000) 813-815
22. Komine M., Nashiro K., Asahina A., et al. Vesicular pemphigoid. Int J Dermatol 31 (1992) 868-870
23. Ueda Y., Nashiro K., Seki Y., et al. Pemphigoid vegetans. Br J Dermatol 120 (1989) 449-453
24. Poulain J.F., Carmi E., Thelu F., et al. Pigmented pemphigoid. Ann Dermatol Venereol 126 (1999) 616-618
25. Cliff S., and Holden C.A. Pemphigoid nodularis: a report of three cases and review of the literature. Br J Dermatol 136 (1997) 398-401
26. Korman N.J., and Woods S.G. Erythrodermic bullous pemphigoid is a clinical variant of bullous pemphigoid. Br J Dermatol 133 (1995) 967-971
27. Alonso-Llamazares J., Dietrich S.M., and Gibson L.E. Bullous pemphigoid presenting as exfoliative erythroderma. J Am Acad Dermatol 39 (1998) 827-830
28. Cordel N., Courville P., Martel P., et al. Extensive erosive bullous pemphigoid: an atypical and serious clinical variant. Br J Dermatol 146 (2002) 537-539
29. Kirtschig G., Chow E.T., Venning V.A., et al. Acquired subepidermal bullous diseases associated with psoriasis: a clinical, immunopathological and immunogenetic study. Br J Dermatol 135 (1996) 738-745
30. Saeki H., Hayashi N., Komine M., et al. A case of generalized pustular psoriasis followed by bullous disease: an atypical case of bullous pemphigoid or a novel bullous disease?. Br J Dermatol 134 (1996) 152-155
31. Sobel S., Miller R., and Shatin H. Lichen planus pemphigoides, immunofluorescence findings. Arch Dermatol 112 (1976) 1280-1283
32. Stingl G., and Hollubar K. Coexistence of lichen planus and bullous pemphigoid. An immunopathological study. Br J Dermatol 93 (1975) 313-320
33. Trueb R.M., Didierjean L., Fellas A., et al. Childhood bullous pemphigoid. Report of a case with characterization of the targeted antigens. J Am Acad Dermatol 40 (1999) 338-344
34. Zillikens D., Caux F., Mascaro J.M., et al. Autoantibodies in lichen planus pemphigoides react with a novel epitope within the C-terminal NC16A domain of BP180. J Invest Dermatol 113 (1999) 117-121
35. Bastuji-Garin S., Joly P., Picard-Dahan C., et al. Drugs associated with bullous pemphigoid. A case-control study. Arch Dermatol 132 (1996) 272-276
36. Vassileva S. Drug-induced pemphigoid: bullous and cicatricial. Clin Dermatol 16 (1998) 379-387
37. Venning V.A., and Wojnarowska F. The association of bullous pemphigoid and malignant disease: a case control study. Br J Dermatol 123 (1990) 439-445
38. Taylor G., Venning V., Wojnarowska F., et al. Bullous pemphigoid and autoimmunity. J Am Acad Dermatol 29 (1993) 181-184
39. Mul V.E., van Geest A.J., Pijls-Johannesma M.C., et al. Radiation-induced bullous pemphigoid: a systematic review of an unusual radiation side effect. Radiother Oncol 82 (2007) 5-9
40. Chan L.S., Vanderlugt C.J., Hashimoto T., et al. Epitope spreading: lessons from autoimmune skin diseases. J Invest Dermatol 110 (1998) 103-109
41. Hofmann S.C., Technau K., Muller A.M., et al. Bullous pemphigoid associated with hypereosinophilic syndrome: simultaneous response to imatinib. J Am Acad Dermatol 56 (2006) S68-S72
42. Chosidow O., Doppler V., Bensimon G., et al. Bullous pemphigoid and amyotrophic lateral sclerosis: a new clue for understanding the bullous disease. Arch Dermatol 136 (2000) 521-524
43. Leung C.L., Zheng M., Prater S.M., et al. The BPAG1 locus: alternative splicing produces multiple isoforms with distinct cytoskeletal linker domains, including predominant isoforms in neurons and muscles. J Cell Biol 154 (2001) 691-697
44. Borradori L., and Sonnenberg A. Structure and function of hemidesmosomes: more than simple adhesion complexes. J Invest Dermatol 112 (1999) 411-418
45. Litjens S.H., de Pereda J.M., and Sonnenberg A. Current insights into the formation and breakdown of hemidesmosomes. Trends Cell Biol 16 (2006) 376-383
46. Giudice G.J., Squiquera H.L., Elias P.M., et al. Identification of two collagen domains within the bullous pemphigoid autoantigen, BP180. J Clin Invest 87 (1991) 734-738
47. Li K.H., Sawamura D., Giudice G.J., et al. Genomic organization of collagenous domains and chromosomal assignment of human 180-kDa bullous pemphigoid antigen-2, a novel collagen of stratified squamous epithelium. J Biol Chem 266 (1991) 24064-24069
48. McGrath J.A., Gatalica B., Christiano A.M., et al. Mutations in the 180-kD bullous pemphigoid antigen (BPAG2), a hemidesmosomal transmembrane collagen (COL17A1), in generalized atrophic benign epidermolysis bullosa. Nat Genet 11 (1995) 83-86
49. Stanley J.R., Tanaka T., Mueller S., et al. Isolation of complementary DNA for bullous pemphigoid antigen by use of patients' autoantibodies. J Clin Invest 82 (1988) 1864-1870
50. Sawamura D., Li K., Chu M.L., et al. Human bullous pemphigoid antigen (BPAG1). Amino acid sequences deduced from cloned cDNAs predict biologically important peptide segments and protein domains. J Biol Chem 266 (1991) 17784-17790
51. Hopkinson S.B., Baker S.E., and Jones J.C. Molecular genetic studies of a human epidermal autoantigen (the 180kD bullous pemphigoid antigen/BP180): identification of functionally important sequences within the BP180 molecule and evidence for an interaction between BP180 and alpha 6 integrin. J Cell Biol 130 (1995) 117-125
52. Borradori L., Koch P.J., Niessen C.M., et al. The localization of bullous pemphigoid antigen 180 (BP180) in hemidesmosomes is mediated by its cytoplasmic domain and seems to be regulated by the beta4 integrin subunit. J Cell Biol 136 (1997) 1333-1347
53. Koster J., Geerts D., Favre B., et al. Analysis of the interactions between BP180, BP230, plectin and the integrin alpha6beta4 important for hemidesmosome assembly. J Cell Sci 116 (2003) 387-399
54. Guo L., Degenstein L., Dowling J., et al. Gene targeting of BPAG1: abnormalities in mechanical strength and cell migration in stratified epithelia and neurologic degeneration. Cell 81 (1995) 233-243
55. Fontao L., Favre B., Riou S., et al. Interaction of the bullous pemphigoid antigen 1 (BP230) and desmoplakin with intermediate filaments is mediated by distinct sequences within their COOH terminus. Mol Biol Cell 14 (2003) 1978-1992
56. Niessen C.M., Hogervorst F., Jaspars L.H., et al. The alpha 6 beta 4 integrin is a receptor for both laminin and kalinin. Exp Cell Res 211 (1994) 360-367
57. Tasanen K., Tunggal L., Chometon G., et al. Keratinocytes from patients lacking collagen XVII display a migratory phenotype. Am J Pathol 164 (2004) 2027-2038
58. Zillikens D., Mascaro J.M., Rose P.A., et al. A highly sensitive enzyme-linked immunosorbent assay for the detection of circulating anti-BP180 autoantibodies in patients with bullous pemphigoid. J Invest Dermatol 109 (1997) 679-683
59. Nakatani C., Muramatsu T., and Shirai T. Immunoreactivity of bullous pemphigoid (BP) autoantibodies against the NC16A and C-terminal domains of the 180 kDa BP antigen (BP180): immunoblot analysis and enzyme-linked immunosorbent assay using BP180 recombinant proteins. Br J Dermatol 139 (1998) 365-370
60. Nie Z., and Hashimoto T. IgA antibodies of cicatricial pemphigoid sera specifically react with C-terminus of BP180. J Invest Dermatol 112 (1999) 254-255
61. Perriard J., Jaunin F., Favre B., et al. IgG autoantibodies from bullous pemphigoid (BP) patients bind antigenic sites on both the extracellular and the intracellular domains of the BP antigen 180. J Invest Dermatol 112 (1999) 141-147
62. Egan C.A., Taylor T.B., Meyer L.J., et al. Bullous pemphigoid sera that contain antibodies to BPAg2 also contain antibodies to LABD97 that recognize epitopes distal to the NC16A domain. J Invest Dermatol 112 (1999) 148-152
63. Schumann H., Baetge J., Tasanen K., et al. The shed ectodomain of collagen XVII/BP180 is targeted by autoantibodies in different blistering skin diseases. Am J Pathol 156 (2000) 685-695
64. Egan C.A., Reddy D., Nie Z., et al. IgG anti-LABD97 antibodies in bullous pemphigoid patients' sera react with the mid-portion of the BPAg2 ectodomain. J Invest Dermatol 116 (2001) 348-350
65. Hofmann S.C., Thoma-Uszynski S., Hunziker T., et al. Severity and phenotype of bullous pemphigoid relate to autoantibody profile against the NH2- and COOH-terminal regions of the BP180 ectodomain. J Invest Dermatol 119 (2002) 1065-1073
66. Thoma-Uszynski S., Uter W., Schwietzke S., et al. Auto-reactive T and B cells from bullous pemphigoid (BP) patients recognize similar antigenic regions of BP180 and BP230. J Immunol 176 (2006) 2015-2023
67. Di Zenzo G., Grosso F., Terracina M., et al. Characterization of the anti-BP180 autoantibody reactivity profile and epitope mapping in bullous pemphigoid patients. J Invest Dermatol 122 (2004) 103-110
68. Mariotti F., Grosso F., Terracina M., et al. Development of a novel ELISA system for detection of anti-BP180 IgG and characterization of autoantibody profile in bullous pemphigoid patients. Br J Dermatol 151 (2004) 1004-1010
69. Leyendeckers H., Tasanen K., Bruckner-Tuderman L., et al. Memory B cells specific for the NC16A domain of the 180 kDa bullous pemphigoid autoantigen can be detected in peripheral blood of bullous pemphigoid patients and induced in vitro to synthesize autoantibodies. J Invest Dermatol 120 (2003) 372-378
70. Rico M.J., Korman N.J., Stanley J.R., et al. IgG antibodies from patients with bullous pemphigoid bind to localized epitopes on synthetic peptides encoded by bullous pemphigoid antigen cDNA. J Immunol 145 (1990) 3728-3733
71. Skaria M., Jaunin F., Hunziker T., et al. IgG autoantibodies from bullous pemphigoid patients recognize multiple antigenic reactive sites located predominantly within the B and C subdomain of the COOH-terminus of BP230. J Invest Dermatol 114 (2000) 998-1004
72. Hamada T., Nagata Y., Tomita M., et al. Bullous pemphigoid sera react specifically with various domains of BP230, most frequently with C-terminal domain, by immunoblot analyses using bacterial recombinant proteins covering the entire molecule. Exp Dermatol 10 (2001) 256-263
73. Tanaka M., Hashimoto T., Amagai M., et al. Characterization of bullous pemphigoid antibodies by use of recombinant bullous pemphigoid antigen proteins. J Invest Dermatol 97 (1991) 725-728
74. Miller J.E., Rico M.J., and Hall III R.P. IgG antibodies from patients with bullous pemphigoid bind to fusion proteins encoded by BPAg1 cDNA. J Invest Dermatol 101 (1993) 779-782
75. Ide A., Hashimoto T., Amagai M., et al. Detection of autoantibodies against bullous pemphigoid and pemphigus antigens by an enzyme-linked immunosorbent assay using the bacterial recombinant proteins. Exp Dermatol 4 (1995) 112-116
76. Gaucherand M., Nicolas J.F., Paranhos Baccala G., et al. Major antigenic epitopes of bullous pemphigoid 230 kDa antigen map within the C-terminal end of the protein. Evidence using a 55 kDa recombinant protein. Br J Dermatol 132 (1995) 190-196
77. Thoma-Uszynski S., Uter W., Schwietzke S., et al. BP230- and BP180-specific auto-antibodies in bullous pemphigoid. J Invest Dermatol 122 (2004) 1413-1422
78. Ghohestani R.F., Cozzani E., Delaporte E., et al. IgE antibodies in sera from patients with bullous pemphigoid are autoantibodies preferentially directed against the 230-kDa epidermal antigen (BP230). J Clin Immunol 18 (1998) 202-209
79. Fairley J.A., Fu C.L., and Giudice G.J. Mapping the binding sites of anti-BP180 immunoglobulin E autoantibodies in bullous pemphigoid. J Invest Dermatol 125 (2005) 467-472
80. Christophoridis S., Büdinger L., Borradori L., et al. IgG, IgA and IgE antibodies against the ectodomain of BP180 in patients with bullous and cicatricial pemphigoid and linear IgA bullous dermatosis. Br J Dermatol 143 (2000) 349-355
81. Vanderlugt C.L., and Miller S.D. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol 2 (2002) 85-95
82. Di Zenzo G., Calabresi V., Grosso F., et al. The intracellular and extracellular domains of BP180 antigen comprise novel epitopes targeted by pemphigoid gestationis autoantibodies. J Invest Dermatol 127 (2007) 864-873
83. Di Zenzo G., Calabresi V., Olasz E.B., et al. Intramolecular epitope spreading against BPAG2 during the humoral response of mice grafted with human BPAG2 (hBPAG2) transgenic skin. J Invest Dermatol 124 (2005) A12
84. Kawahara Y., Amagai M., Ohata Y., et al. A case of cicatricial pemphigoid with simultaneous IgG autoantibodies against the 180 kD bullous pemphigoid antigen and laminin 5. J Am Acad Dermatol 38 (1998) 624-627
85. Laffitte E., Favre B., Fontao L., et al. Plectin, an unusual target antigen in bullous pemphigoid. Br J Dermatol 144 (2001) 136-138
86. Budinger L., Borradori L., Yee C., et al. Identification and characterization of autoreactive T cell responses to bullous pemphigoid antigen 2 in patients and healthy controls. J Clin Invest 102 (1998) 2082-2089
87. Lin M.S., Gharia M.A., Swartz S.J., et al. Identification and characterization of epitopes recognized by T lymphocytes and autoantibodies from patients with herpes gestationis. J Immunol 162 (1999) 4991-4997
88. Lin M.S., Fu C.L., Giudice G.J., et al. Epitopes targeted by bullous pemphigoid T lymphocytes and autoantibodies map to the same sites on the bullous pemphigoid 180 ectodomain. J Invest Dermatol 115 (2000) 955-961
89. Romagnani S. Human TH1 and TH2 subsets: regulation of differentiation and role in protection and immunopathology. Int Arch Allergy Appl Immunol 98 (1992) 279-285
90. D'Auria L., Mussi A., Bonifati C., et al. Increased serum IL-6, TNF-alpha and IL-10 levels in patients with bullous pemphigoid: relationships with disease activity. J Eur Acad Dermatol Venereol 12 (1999) 11-15
91. Gammon W.R., Inman III A.O., and Wheeler Jr. C.E. Differences in complement-dependent chemotactic activity generated by bullous pemphigoid and epidermolysis bullosa acquisita immune complexes: demonstration by leukocytic attachment and organ culture methods. J Invest Dermatol 83 (1984) 57-61
92. Stahle-Backdahl M., Inoue M., Guidice G.J., et al. 92-kD gelatinase is produced by eosinophils at the site of blister formation in bullous pemphigoid and cleaves the extracellular domain of recombinant 180-kD bullous pemphigoid autoantigen. J Clin Invest 93 (1994) 2022-2030
93. Verraes S., Hornebeck W., Polette M., et al. Respective contribution of neutrophil elastase and matrix metalloproteinase 9 in the degradation of BP180 (type XVII collagen) in human bullous pemphigoid. J Invest Dermatol 117 (2001) 1091-1096
94. Niimi Y., Pawankar R., and Kawana S. Increased expression of matrix metalloproteinase-2, matrix metalloproteinase-9 and matrix metalloproteinase-13 in lesional skin of bullous pemphigoid. Int Arch Allergy Immunol 139 (2006) 104-113
95. Diaz L.A., and Anhalt G.J. Bullous pemphigoid and other basement membrane antigens. Clin Dermatol 5 (1987) 93-109
96. Liu Z., Diaz L.A., Troy J.L., et al. A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180. J Clin Invest 92 (1993) 2480-2488
97. Muller-Eberhard H.J. Molecular organization and function of the complement system. Annu Rev Biochem 57 (1988) 321-347
98. Liu Z., Giudice G.J., Swartz S.J., et al. The role of complement in experimental bullous pemphigoid. J Clin Invest 95 (1995) 1539-1544
99. Yamamoto K., Inoue N., Masuda R., et al. Cloning of hamster type XVII collagen cDNA, and pathogenesis of anti-type XVII collagen antibody and complement in hamster bullous pemphigoid. J Invest Dermatol 118 (2002) 485-492
100. Nelson K.C., Zhao M., Schroeder P.R., et al. Role of different pathways of the complement cascade in experimental bullous pemphigoid. J Clin Invest 116 (2006) 2892-2900
101. Chen R., Ning G., Zhao M.L., et al. Mast cells play a key role in neutrophil recruitment in experimental bullous pemphigoid. J Clin Invest 108 (2001) 1151-1158
102. Chen R., Fairley J.A., Zhao M.L., et al. Macrophages, but not T and B lymphocytes, are critical for subepidermal blister formation in experimental bullous pemphigoid: macrophage-mediated neutrophil infiltration depends on mast cell activation. J Immunol 169 (2002) 3987-3992
103. Dimson O.G., Giudice G.J., Fu C.L., et al. Identification of a potential effector function for IgE autoantibodies in the organ-specific autoimmune disease bullous pemphigoid. J Invest Dermatol 120 (2003) 784-788
104. Liu Z., Giudice G.J., Zhou X., et al. A major role for neutrophils in experimental bullous pemphigoid. J Clin Invest 100 (1997) 1256-1263
105. Zhao M., Trimbeger M.E., Li N., et al. Role of FcRs in animal model of autoimmune bullous pemphigoid. J Immunol 177 (2006) 3398-3405
106. Liu Z., Shipley J.M., Vu T.H., et al. Gelatinase B-deficient mice are resistant to experimental bullous pemphigoid. J Exp Med 188 (1998) 475-482
107. Liu Z., Shapiro S.D., Zhou X., et al. A critical role for neutrophil elastase in experimental bullous pemphigoid. J Clin Invest 105 (2000) 113-123
108. Liu Z., Zhou X., Shapiro S.D., et al. The serpin alpha1-proteinase inhibitor is a critical substrate for gelatinase B/MMP-9 in vivo. Cell 102 (2000) 647-655
109. Liu Z., Li N., Diaz L.A., et al. Synergy between a plasminogen cascade and MMP-9 in autoimmune disease. J Clin Invest 115 (2005) 879-887
110. Gammon W.R., Merritt C.C., Lewis D.M., et al. An in vitro model of immune complex-mediated basement membrane zone separation caused by pemphigoid antibodies, leukocytes, and complement. J Invest Dermatol 78 (1982) 285-290
111. Sitaru C., Schmidt E., Petermann S., et al. Autoantibodies to bullous pemphigoid antigen 180 induce dermal-epidermal separation in cryosections of human skin. J Invest Dermatol 118 (2002) 664-671
112. Herrero-Gonzalez J.E., Brauns O., Egner R., et al. Immunoadsorption against two distinct epitopes on human type XVII collagen abolishes dermal-epidermal separation induced in vitro by autoantibodies from pemphigoid gestationis patients. Eur J Immunol 36 (2006) 1039-1048
113. Shimanovich I., Mihai S., Oostingh G.J., et al. Granulocyte-derived elastase and gelatinase B are required for dermal-epidermal separation induced by autoantibodies from patients with epidermolysis bullosa acquisita and bullous pemphigoid. J Pathol 204 (2004) 519-527
114. Liu Z., Sui W., Zhao M., et al. Induction of bullous pemphigoid and pemphigoid gestationis in humanized BP180NC16A mice by passive transfer of autoantibodies from patients. J Invest Dermatol 126 (2006) s21
115. Nishie W., Sawamura D., Goto M., et al. Humanization of autoantigen. Nat Med 13 (2007) 378-383
116. Hall III R.P., Murray J.C., McCord M.M., et al. Rabbits immunized with a peptide encoded for by the 230-kd bullous pemphigoid antigen cDNA develop an enhanced inflammatory response to UVB irradiation: a potential animal model for bullous pemphigoid. J Invest Dermatol 101 (1993) 9-14
117. Kiss M., Husz S., Janossy T., et al. Experimental bullous pemphigoid generated in mice with an antigenic epitope of the human hemidesmosomal protein BP230. J Autoimmun 24 (2005) 1-10
118. Olivry T., Chan L.S., Xu L., et al. Novel feline autoimmune blistering disease resembling bullous pemphigoid in humans: IgG autoantibodies target the NC16A ectodomain of type XVII collagen (BP180/BPAG2). Vet Pathol 36 (1999) 328-335
119. Olivry T., Mirsky M.L., Singleton W., et al. A spontaneously arising porcine model of bullous pemphigoid. Arch Dermatol Res 292 (2000) 37-45
120. Olivry T., Borrillo A.K., Xu L., et al. Equine bullous pemphigoid IgG autoantibodies target linear epitopes in the NC16A ectodomain of collagen XVII (BP180, BPAG2). Vet Immunol Immunopathol 73 (2000) 45-52
121. Vaillant L., Bernard P., Joly P., et al. Evaluation of clinical criteria for diagnosis of bullous pemphigoid. French Bullous Study Group. Arch Dermatol 134 (1998) 1075-1080
122. Joly P., Courville P., Lok C., et al. Clinical criteria for the diagnosis of bullous pemphigoid: a reevaluation according to immunoblot analysis of patient sera. Dermatology 208 (2004) 16-20
123. Gammon W.R., Kowalewski C., Chorzelski T.P., et al. Direct immunofluorescence studies of sodium chloride-separated skin in the differential diagnosis of bullous pemphigoid and epidermolysis bullosa acquisita. J Am Acad Dermatol 22 (1990) 664-670
124. De Jong M.C., Bruins S., Heeres K., et al. Bullous pemphigoid and epidermolysis bullosa acquisita. Differentiation by fluorescence overlay antigen mapping. Arch Dermatol 132 (1996) 151-157
125. Vodegel R.M., Jonkman M.F., Pas H.H., et al. U-serrated immunodeposition pattern differentiates type VII collagen targeting bullous diseases from other subepidermal bullous autoimmune diseases. Br J Dermatol 151 (2004) 112-118
126. Vodegel R.M., De Jong M.C., Meijer H.J., et al. Enhanced diagnostic immunofluorescence using biopsies transported in saline. BMC Dermatol 4 (2004) 10
127. Gammon W.R., Fine J.D., Forbes M., et al. Immunofluorescence on split skin for the detection and differentiation of basement membrane zone autoantibodies. J Am Acad Dermatol 27 (1992) 79-87
128. Labib R.S., Anhalt G.J., Patel H.P., et al. Molecular heterogeneity of the bullous pemphigoid antigens as detected by immunoblotting. J Immunol 136 (1986) 1231-1235
129. Ghohestani R., Kanitakis J., Nicolas J.F., et al. Comparative sensitivity of indirect immunofluorescence to immunoblot assay for the detection of circulating antibodies to bullous pemphigoid antigens 1 and 2. Br J Dermatol 135 (1996) 74-79
130. Murakami H., Amagai M., Higashiyama M., et al. Analysis of antigens recognized by autoantibodies in herpes gestationis. Usefulness of immunoblotting using a fusion protein representing an extracellular domain of the 180 kD bullous pemphigoid antigen. J Dermatol Sci 13 (1996) 112-117
131. Yoshida M., Hamada T., Amagai M., et al. Enzyme-linked immunosorbent assay using bacterial recombinant proteins of human BP230 as a diagnostic tool for bullous pemphigoid. J Dermatol Sci 41 (2006) 21-30
132. Kromminga A., Sitaru C., Hagel C., et al. Development of an ELISA for the detection of autoantibodies to BP230. Clin Immunol 111 (2004) 146-152
133. Sakuma-Oyama Y., Powell A.M., Oyama N., et al. Evaluation of a BP180-NC16a enzyme-linked immunosorbent assay in the initial diagnosis of bullous pemphigoid. Br J Dermatol 151 (2004) 126-131
134. Tsuji-Abe Y., Akiyama M., Yamanaka Y., et al. Correlation of clinical severity and ELISA indices for the NC16A domain of BP180 measured using BP180 ELISA kit in bullous pemphigoid. J Dermatol Sci 37 (2005) 145-149
135. Powell A.M., Sakuma-Oyama Y., Oyama N., et al. Usefulness of BP180 NC16a enzyme-linked immunosorbent assay in the serodiagnosis of pemphigoid gestationis and in differentiating between pemphigoid gestationis and pruritic urticarial papules and plaques of pregnancy. Arch Dermatol 141 (2005) 705-710
136. Wojnarowska F., Kirtschig G., Highet A.S., et al. Guidelines for the management of bullous pemphigoid. Br J Dermatol 147 (2002) 214-221
137. Khumalo N., Kirtschig G., Middleton P., et al. Interventions for bullous pemphigoid. Cochrane Database Syst 3 (2005) CD002292
138. Patton T., and Korman N.J. Bullous pemphigoid treatment review. Expert Opin Pharmacother 7 (2006) 2403-2411
139. Joly P., Roujeau J.C., Benichou J., et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med 346 (2002) 321-327
140. Morel P., and Guillaume J.C. Treatment of bullous pemphigoid with prednisolone only: 0.75 mg/kg/day versus 1.25 mg/kg/day. A multicenter randomized study. Ann Dermatol Venereol 111 (1984) 925-928
141. Roujeau J.C., Guillaume J.C., Morel P., et al. Plasma exchange in bullous pemphigoid. Lancet 2 (1984) 486-488
142. Dreno B., Sassolas B., Lacour P., et al. Methylprednisolone versus prednisolone methylsulfobenzoate in pemphigoid: a comparative multicenter study. Ann Dermatol Venereol 120 (1993) 518-521
143. Joly P., Roujeau J., Delaporte E., et al. Comparaison de deux stratégies thérapeutiques de corticothérapie locale dans le traitement de la pemphigoïde bulleuse. Ann Dermatol Venereol 133 (2006) 4S3 -C4
144. Guillaume J.C., Vaillant L., Bernard P., et al. Controlled trial of azathioprine and plasma exchange in addition to prednisolone in the treatment of bullous pemphigoid. Arch Dermatol 129 (1993) 49-53
145. Fivenson D.P., Breneman D.L., Rosen G.B., et al. Nicotinamide and tetracycline therapy of bullous pemphigoid. Arch Dermatol 130 (1994) 753-758
146. Chu J., Bradley M., and Marinkovich M.P. Topical tacrolimus is a useful adjunctive therapy for bullous pemphigoid. Arch Dermatol 139 (2003) 813-815
147. Ko M.J., and Chu C.Y. Topical tacrolimus therapy for localized bullous pemphigoid. Br J Dermatol 149 (2003) 1079-1081
148. Ahmed A.R. Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment. J Am Acad Dermatol 45 (2001) 825-835
149. Guillot B., Donadio D., Guilhou J.J., et al. Long term plasma exchange therapy in bullous pemphigoid. Acta Derm Venereol 66 (1986) 73-75
150. Szabolcs P., Reese M., Yancey K.B., et al. Combination treatment of bullous pemphigoid with anti-CD20 and anti-CD25 antibodies in a patient with chronic graft-versus-host disease. Bone Marrow Transplant 30 (2002) 327-329
151. Roujeau J.C., Lok C., Bastuji-Garin S., et al. High risk of death in elderly patients with extensive bullous pemphigoid. Arch Dermatol 134 (1998) 465-469
152. Bystryn J.C., and Rudolph J.L. Why is the mortality of bullous pemphigoid greater in Europe than in the US?. J Invest Dermatol 124 (2005) xx-xxi
153. Joly P., Benichou J., Saiag P., et al. Response to: mortality rate of bullous pemphigoid in a US medical center. J Invest Dermatol 124 (2005) 664-665
154. Joly P., Benichou J., Lok C., et al. Prediction of survival for patients with bullous pemphigoid: a prospective study. Arch Dermatol 141 (2005) 691-698
155. Rzany B., Partscht K., Jung M., et al. Risk factors for lethal outcome in patients with bullous pemphigoid: low serum albumin level, high dosage of glucocorticosteroids, and old age. Arch Dermatol 138 (2002) 903-908
156. Bernard P., Bedane C., and Bonnetblanc M. Anti-BP180 autoantibodies as a marker of poor prognosis in bullous pemphigoid: a cohort analysis of 94 elderly patients. Br J Dermatol 136 (1997) 694-698
157. Pfütze M., Niedermeier A., Hertl M., et al. Introducing a novel autoimmune bullous skin disorder intensity score (ABSIS) in pemphigus. Eur J Dermatol 17 (2007) 4-11
158. Dopp R., Schmidt E., Chimanovitch I., et al. IgG4 and IgE are the major immunoglobulins targeting the NC16A domain of BP180 in bullous pemphigoid: serum levels of these immunoglobulins reflect disease activity. J Am Acad Dermatol 42 (2000) 577-583
159. Schmidt E., Obe K., Brocker E.B., et al. Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid. Arch Dermatol 136 (2000) 174-178
160. Amo Y., Ohkawa T., Tatsuta M., et al. Clinical significance of enzyme-linked immunosorbent assay for the detection of circulating anti-BP180 autoantibodies in patients with bullous pemphigoid. J Dermatol Sci 26 (2001) 14-18
161. Kobayashi M., Amagai M., Kuroda-Kinoshita K., et al. BP180 ELISA using bacterial recombinant NC16a protein as a diagnostic and monitoring tool for bullous pemphigoid. J Dermatol Sci 30 (2002) 224-232
162. Reguiaï Z., Tancrède-Bohin E., Cordel N., et al. La positivité de l'immunofluorescence directe à l'arrêt de la corticothérapie est le principal facteur prédictif de rechute de pemphigoïde bulleuse. Ann Dermatol Venereol 133 (2006) 4S2 -C3
163. Husz S., Kiss M., Molnar K., et al. Development of a system for detection of circulating antibodies against hemdesmosomal proteins in patients with bullous pemphigoid. Arch Dermatol Res 292 (2000) 217-224
164. Hata Y., Fujii Y., Tssunoda K., et al. Production of the entire extracellular domain of BP180 (type XVII collagen) by baculovirus expression. J Dermatol Sci 23 (2000) 183-190